No Data
Private Companies Are KPC Pharmaceuticals,Inc.'s (SHSE:600422) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥462m Last Week
KPC Pharmaceuticals Secures Drug Marketing Authorization for Mycophenolate Mofetil
KPC Pharmaceuticals, Inc. (600422.SH): The drug application for the suspension of mycophenolate mofetil has been accepted.
On January 14, Glonghui reported that KPC Pharmaceuticals, Inc. (600422.SH) announced that its wholly-owned subsidiary Kunming Beikenuodun Pharmaceutical Co., Ltd. recently received the "Acceptance Notice" issued by the National Medical Products Administration, and the drug marketing authorization application for the dry suspension of Mycophenolate Mofetil was accepted by the National Medical Products Administration. Mycophenolate Mofetil was developed by Roche and was approved for marketing in the European Union and the USA in 1996 and 1998, respectively, primarily used for the prevention of rejection after kidney, heart, and liver transplants; it was launched in Japan in 2015, and the current indications, in addition to use for organ transplant rejection, ...
KPC Pharmaceuticals, Inc. (600422.SH): Participating in the centralized procurement of the National Chinese Patent Medicine Purchasing Alliance is expected to be selected.
On January 2, Gelonghui reported that KPC Pharmaceuticals, Inc. (600422.SH) announced that on December 30, 2024, the company and its subsidiaries participated in the bidding for the national Chinese Patent Medicine procurement alliance centralized procurement (the first batch of expansion continuation) organized by the National Chinese Patent Medicine Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office"). According to the "Public Notice of Proposed Selected Results for National Chinese Patent Medicine Procurement Alliance Centralized Volume Procurement" released by the Joint Procurement Office, the company's injectable Xuesaitong (freeze-dried), KPC Pharmaceuticals, Inc. Xuesaitong Pharmaceutical Co., Ltd. (hereinafter referred to as "Xuesaitong Pharmaceutical") Xuesaitong滴丸, Kunming China Resources Holy Fire Pharmaceutical Co., Ltd.
KPC PharmaceuticalsInc (SHSE:600422) Seems To Use Debt Quite Sensibly
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
KPC Pharmaceuticals,Inc (SHSE:600422) Not Lagging Market On Growth Or Pricing